CJC-1295 Benefits
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
How CJC-1295 works
CJC-1295 acts as a GHRH receptor (GHRHR) agonist on somatotroph cells of the anterior pituitary gland. Upon binding to GHRHR, it activates adenylyl cyclase through Gs protein coupling, increasing intracellular cAMP and activating protein kinase A (PKA). This signaling cascade stimulates both the synthesis and secretion of growth hormone. The DAC version achieves its extended duration through a maleimidopropionic acid linker that forms a covalent thioether bond with Cys34 on circulating serum albumin. This albumin conjugation prevents enzymatic cleavage by DPP-IV and other peptidases while maintaining receptor binding activity. The original discovery paper showed CJC-1295 produced a 4-fold increase in GH area under the curve compared to standard GRF(1-29) in preclinical models, with the compound detectable in plasma beyond 72 hours post-injection (PMID: 15817669). The no-DAC version (mod GRF 1-29) achieves improved stability through four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) that resist DPP-IV degradation while preserving full GHRHR binding affinity. Without albumin conjugation, it clears rapidly after each injection, producing discrete GH pulses that more closely mirror the body's natural secretory pattern. Both forms preserve the somatostatin negative feedback loop — the hypothalamic brake on GH secretion. This means the body retains its ability to regulate GH levels, reducing the risk of GH excess compared to direct HGH injection. GH secreted in response to CJC-1295 stimulates hepatic IGF-I production, which mediates many downstream anabolic and metabolic effects including protein synthesis, lipolysis, and cellular repair.
Reported benefits
Based on available research data, CJC-1295 has been associated with the following benefits:
- Sustained GH elevation: single DAC injection produced 2- to 10-fold GH increases for 6+ days, with IGF-I rising 1.5- to 3-fold for 9-11 days in healthy adults (PMID: 16352683)
- Preserved GH pulse pattern: basal GH increased 7.5-fold while pulse frequency and magnitude remained unchanged (PMID: 17018654). Note that while the pulse pattern is preserved, the baseline GH floor is significantly elevated — the rhythm is intact but at a non-physiological level, particularly with the DAC version
- Body composition improvement: GHRH analog administration in adults ages 55-71 increased lean body mass and improved insulin sensitivity in men over 16 weeks (PMID: 9141536)
- Muscle density and area: the related GHRH analog tesamorelin significantly increased muscle density and lean muscle area across 4 trunk muscle groups vs placebo among treatment responders in an RCT (PMID: 31237318)
- Age-related GH restoration: twice-daily GRF(1-29) at the highest tested dose eliminated age-related differences in GH and IGF-I between young and elderly men within 14 days in a small study (n=10) (PMID: 1379256)
- Sleep architecture improvement: GHRH class compounds promote slow-wave sleep — GHRH administered during the third REM period increased SWS nearly 10-fold in a controlled study (PMID: 8476038)
- Extended dosing convenience: DAC version half-life of 5.8-8.1 days permits weekly or twice-weekly dosing instead of multiple daily injections (PMID: 16352683)
- Synergistic with ipamorelin: the CJC-1295 + ipamorelin combination targets two different pathways (GHRHR and GHS-R1a), producing amplified GH release without elevating cortisol or prolactin (PMID: 9849822)
- Improved skin thickness: GHRH analog treatment significantly increased skin thickness in both men and women over 16 weeks (PMID: 9141536)
- Growth normalization: daily CJC-1295 normalized body weight, length, and composition in GHRH-deficient animal models via restored GH axis signaling (PMID: 16822960)
- Enhanced recovery: GH elevation promotes protein synthesis, collagen production, and cellular repair mechanisms relevant to exercise recovery and tissue regeneration
- Metabolic support: GH secretagogues may improve fat distribution and ameliorate metabolic symptoms associated with low GH status (PMID: 32257855)
- Feedback loop preservation: somatostatin negative feedback remains intact, reducing the risk of acute supraphysiologic GH peaks compared to exogenous HGH. However, sustained GH/IGF-1 elevation can still produce insulin resistance and fluid retention even with feedback preserved (PMID: 28400207)
- Biomarker improvements: serum protein analysis showed CJC-1295 modulated apolipoprotein and immunoglobulin profiles with linear correlation to IGF-1 changes (PMID: 19386527)
Supporting research
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Journal of Clinical Endocrinology & Metabolism, 2006 · PMID: 16352683
Single injection produced dose-dependent GH increases of 2- to 10-fold sustained for 6+ days. IGF-I increased 1.5- to 3-fold for 9-11 days. Half-life: 5.8-8.1 days. No serious adverse events in healthy adults ages 21-61.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Journal of Clinical Endocrinology & Metabolism, 2006 · PMID: 17018654
Basal GH levels increased 7.5-fold (p < 0.0001) and overall mean GH rose 46% (p < 0.01) while GH pulse frequency and magnitude remained unchanged, confirming preserved pulsatility even with continuous GHRHR stimulation.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Growth Hormone & IGF Research, 2009 · PMID: 19386527
Identified specific serum protein changes in 11 healthy men following CJC-1295 injection, including decreased apolipoprotein A1 and upregulated beta-hemoglobin and albumin fragments, with linear correlation between immunoglobulin-albumin changes and IGF-1 levels.
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Endocrinology, 2005 · PMID: 15817669
Original discovery paper. CJC-1295 produced a 4-fold increase in GH area under the curve compared to standard GRF(1-29). Albumin-bound compound remained detectable in plasma beyond 72 hours post-injection.
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
American Journal of Physiology — Endocrinology and Metabolism, 2006 · PMID: 16822960
Daily CJC-1295 normalized body weight, length, and body composition in GHRH knockout mice. Stimulated pituitary GH gene transcription and somatotroph cell proliferation, maintaining normal growth via restored GH axis signaling.
Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
Journal of Clinical Endocrinology & Metabolism, 1992 · PMID: 1379256
High-dose GRF(1-29) twice daily for 14 days eliminated age-related differences in 24-hour GH and IGF-I between young men (avg age 26) and elderly men (avg age 68, n=10) at the highest tested dose.
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women
Journal of Clinical Endocrinology & Metabolism, 1997 · PMID: 9141536
16-week RCT in adults ages 55-71. Men showed increased lean body mass, improved insulin sensitivity, enhanced wellbeing and libido. Women showed increased skin thickness. IGF-I and IGFBP-3 rose within 2 weeks in both sexes.
The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV
Journal of Frailty and Aging, 2019 · PMID: 31237318
RCT responder sub-analysis: among tesamorelin responders (n=193 vs 148 placebo), the GHRH analog significantly increased muscle density and lean muscle area across 4 trunk muscle groups vs placebo. This was a responder analysis (VAT decrease >= 8%), not intent-to-treat.
Ipamorelin, the first selective growth hormone secretagogue
European Journal of Endocrinology, 1998 · PMID: 9849822
Established ipamorelin as the first GH secretagogue with selectivity matching GHRH — it releases GH without elevating ACTH or cortisol even at 200 times the effective dose, unlike GHRP-6 and GHRP-2. This selectivity profile makes it the rational pairing partner for CJC-1295.
The safety and efficacy of growth hormone secretagogues
Sexual Medicine Reviews, 2018 · PMID: 28400207
Systematic review: GH secretagogues promote pulsatile GH release subject to negative feedback, may improve growth velocity, lean mass, fat distribution, bone turnover, and sleep. Well tolerated but some concern for decreased insulin sensitivity. Long-term safety data needed.
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Translational Andrology and Urology, 2020 · PMID: 32257855
Review: GH secretagogues are potent GH and IGF-1 stimulators that significantly improve body composition and can ameliorate hypogonadal symptoms including fat gain and muscular atrophy. Notes the paucity of long-term clinical data.
Sleep-promoting effects of growth hormone-releasing hormone in normal men
American Journal of Physiology, 1993 · PMID: 8476038
GHRH administered during the third REM period of late sleep increased slow-wave sleep nearly 10-fold. In a separate sleep deprivation arm, GHRH reduced waking time during the subsequent slow-wave period. Two distinct experimental conditions showing GHRH promotes SWS.
Advances in the detection of growth hormone releasing hormone synthetic analogs
Drug Testing and Analysis, 2021 · PMID: 34665524
Identified 19 major in vitro metabolites of CJC-1295 (both DAC and no-DAC forms) and related GHRH analogs. Detection limits achieved at or below WADA's 1 ng/ml performance threshold, confirming robust anti-doping detection capability.
Chemical modification of Class II G-protein coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies
Pharmacology & Therapeutics, 2010 · PMID: 19686775
Review of chemical modifications to GPCR peptide ligands including GHRH analogs. Discusses albumin-binding strategies for extending peptide half-lives. CJC-1295 is referenced as an example of successful bioconjugation approach. Specific pharmacokinetic data (half-life, fold-improvement) available in full text.
Important context
Benefits reported in clinical trials represent average outcomes across study populations. Individual results vary based on genetics, dosage, duration, and lifestyle factors. This compound is not FDA-approved for human use. Benefits described are based on research data and should not be interpreted as therapeutic claims.
Related peptides
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.